AFP and hepatocellular carcinoma: The miR-21 fold changes in AFP producing HCC patients can also predict post-LRT tumor response with AUC of 0.640 (95% CI, 0.459–0.822) for CR+PR vs. PD, group 1 (Figure 4Bi); with AUC, 0.729 (95% CI, 0.579–0.881) for CR vs. PR+PD, group 2 (Figure 4Bii) and AUC, 0.722 (95%, 0.539–0.904) for CR vs. PD patients (Figure 4Biii).